H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while boosting its price target to $25 from $15 on January 28, following the removal of a clinical hold on the company’s MAGNITUDE-2 study. Pixabay/Public Domain The updated protocol raises the target enrollment to around 60 patients from the originally intended 50, implying a focus on improving ris ...